Treatment with a CB1 agonist increases de novo fatty acid synthesis in the liver or isolated hepatocytes, thus contributing to diet-induced obesity [15] and strongly suggesting a role in the progress of obesity and its comorbidities. Here, CNR1 is linked to obesity disorder.